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Abstract
Objectives To quantify the life years gained and lifetime healthcare cost savings 
by preventing a case of malignant pleural mesothelioma (MPM).
Methods We retrieved data from the Taiwan Cancer Registry (TCR) and linked 
them with the National Mortality Registry to estimate the survival functions for 
malignant pleural mesothelioma, an asbestos-related malignancy.  We also 
retrieved cases of pleural cancer registered in the catastrophic illnesses of the 
National Health Insurance Research Database (NHIRD) to cross-validate the 
results.  Assuming a constant excess hazard, we extrapolated lifetime survival 
function by the Monte Carlo method.  For each MPM patient, we simulated an 
age- and gender-matched person without cancer based on the vital statistics of 
Taiwan to estimate life expectancy and expected years of life lost (EYLL).  By 
using the reimbursement data from the NHIRD, we calculated the average 
monthly healthcare expenditures, which were summed to estimate the lifetime 
healthcare expenditures after adjusting for the corresponding monthly survival 
probability.
Results A total of 503 cases of MPM were identified in the NHIRD during 1997 ~ 
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2008.  The average EYLL was predicted to be 15.1 (95% confidence interval [CI]: 
14.1 ~ 16.1) years, and the lifetime healthcare expenditures with a 3% annual 
discount were predicted to be $19,615 (95% CI:  14,505.3 ~ 24,724.7) US dollars.
Conclusions The burden of MPM, in terms of EYLL and lifetime healthcare 
expenditures, was substantial.  Such estimates may provide useful empirical 
evidence for clinical and health policy-making.
Key words :  malignant pleural mesothelioma (MPM), asbestos, expected years of 
life lost (EYLL), life expectancy, lifetime healthcare expenditure
Abbreviations:
CI confidence interval
EYLL expected years of life lost
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical 
Modification
ICD-O International Classification of Diseases for Oncology
MPM malignant pleural mesothelioma
NHI National Health Insurance
NHIRD National Health Insurance Research Database
TCR Taiwan Cancer Registry
INTRODUCTION
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the 
serosal lining of the pleural cavity arising from mesothelial cells (1, 2).  Patients 
with MPM have poor prognosis and the median survival time was reported 
between 8 ~ 19 months even with advanced treatment (3, 4).  MPM has become a 
major public health problem worldwide because of its global epidemic associated 
with previous usage of asbestos (5-9).  In many developed countries, the expected 
number of MPM-related deaths is projected to increase up to a peak in the next 
several decades (10-12).  Unfortunately, asbestos are still imported and in use in 
almost all counties in Eastern Europe, Latin America, Africa, and Asia, including 
China, Thailand, and Taiwan (13, 14).  In Taiwan, an increasing trend of incidence 
of malignant mesothelioma both in males and females has been observed (15), 
even though the incidence rate seems not so high, i.e., 1.14 cases per million per 
year (16), near the background incidence (1 ~ 2 cases/million/year) in the western 
countries.  The low incidence rates of mesothelioma in Taiwan and many other 
countries in Asia is likely due to the limited public health infrastructure that 
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mesothelioma has been under-reported or even no reliable incidence data are 
available.  The Asian countries where asbestos is still in use but have not reported 
asbestos-related diseases properly are likely to be the areas where the asbestos 
epidemic is just beginning to develop currently with insufficient latency period  (5).
A body of evidence has indicated a causal link between exposure to asbestos 
and the development of MPM (17, 18).  An international analysis demonstrates an 
ecological association between increased risk of mesothelioma and population 
exposure to asbestos over the past three to four decades (8).  Because MPM is 
primarily caused by asbestos exposure  (3, 17, 18), it can be considered as a signal 
tumour of exposure to asbestos (19).  A recent study in the UK estimated the 
attributable fraction of asbestos among male mesothelioma cases from 
occupational, paraoccupational and environmental sources to be 96 ~ 98% (20).  In 
contrast, another study suggested a more limited role of occupational exposure to 
asbestos in the aetiology of peritoneal mesothelioma than for pleural 
mesothelioma (21).  There is also diagnostic uncertainty in classification of 
peritoneal tumour based on the International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9-CM) code because ovarian and 
gastrointestinal tumours may be misdiagnosed as peritoneal mesothelioma and 
vice versa (21, 22).  Among peritoneal mesothelioma, well-differentiated papillary 
and cystic mesotheliomas are unrelated to asbestos exposure, and usually occur in 
women and have a good prognosis (3, 22).  Thus, it is reasonable to use MPM as 
the malignancy of interest closely related to asbestos exposure.  The burden of 
disease caused by asbestos have a substantial impact on quality and quantity of 
life in general population with potential exposure from the workplace and 
residential environment, as well as may exert financial impact on patients, their 
families and the society.  However, the economic costs of asbestos-related diseases 
to the society remain to be elucidated (23, 24).  It is important to quantify the 
disease burden caused by MPM to facilitate the outcome research and cost-
effectiveness analysis for prevention of asbestos-related diseases.  We therefore 
conducted this study to estimate the expected years of life lost (EYLL) and 
lifetime direct medical costs for a case of MPM in Taiwan.
METHODS
This study began after the approval of the Institutional Review Board of the 
National Taiwan University Hospital (NTUH IRB no. 200808029R) and National 
Health Research Institutes (NHRI IRB no. EC0991104-E).  We used two different 
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datasets to cross-validate the estimation of the survival functions in this study: 
the Taiwan Cancer Registry (TCR) and the National Health Insurance Research 
Database (NHIRD).
Taiwan Cancer Registry (TCR) 
We analysed information on the cases registered in the TCR between January 
1997 and December 2005.  We identified all cases of histopathologically verified 
malignant pleural mesothelioma (MPM), coded according to the International 
Classification of Diseases for Oncology (ICD-O) (25), i.e., ICD-O code 163 for 
cancer site of the pleura, and morphology codes 9050/3, 9051/3, 9052/3, and 
9053/3.  Only patients aged 18 years or older with definite histopathological 
evidence of MPM were included in this study.
A total of 144 patients were identified with the diagnoses MPM from 1 
January 1997 to 31 December 2005.  The dataset was then linked with the 
National Mortality Registry database to verify the vital status for each case until 
the end of 2007.
National Health Insurance Research Database (NHIRD) 
The reimbursement data of the NHIRD for the period from 1997 to 2008, 
which contained data for all outpatients and inpatients with diagnoses of pleural 
cancer, were also utilised.  Taiwan established a single-payer, universal National 
Health Insurance (NHI) program in 1995.  By 2009, the NHI covered 99% of 
Taiwan’s twenty-three million people (26, 27).  The NHIRD consists of original 
claims data for reimbursement and a registry of all enrolees, which allowed 
researchers to trace all medical services received by enrolees under the NHI 
program. To secure the protection of personal confidentiality, all the personal 
identification numbers were encrypted, and the reimbursement data were 
transformed into a research database, namely the NHIRD, which were regularly 
maintained by the National Health Research Institutes.  Taiwan’s NHI covers 
almost all healthcare services for catastrophic illnesses, except some novel 
technologies and medications for which there is no evidenced-based consensus on 
their effectiveness.  As all types of cancer can be registered as a catastrophic 
illness and treated without copayments, the criteria for the registration were very 
strict and established by the medical specialty boards and the Bureau of NHI. 
Based on the annual reports of TCR, MPM accounted for the majority (about 80% 
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of all pathological types) of malignant neoplasm of the pleura (28).  We thus 
assumed that the pleural cancer, which was coded as ICD-9-CM code 163 in the 
NHIRD, was MPM for the purpose of cost estimation.  Therefore, we only included 
the cases of MPM (or pleural cancer) that were successfully registered in the 
dataset of catastrophic illnesses from 1 January 1997 to 31 December 2008.
Extrapolation method to obtain lifetime survival functions
Monte Carlo simulation was used to extrapolate survival for up to 50 years to 
derive the lifetime survival function after the diagnosis of MPM.  Briefly, the 
survival function for an age- and gender-matched reference population was 
generated using the Monte Carlo method from the life tables of the general 
population of Taiwan in the corresponding year.  The life tables of the general 
population were obtained from vital statistics published annually by the 
Department of Statistics, Ministry of the Interior, Executive Yuan of Taiwan. 
Because individual survival time of subjects in a hypothetical cohort cannot be 
directly derived from the life tables of the general population, we used a Monte 
Carlo method to generate the simulated remaining survival time of age- and 
gender-matched hypothetical subjects for each patient in the MPM cohort.
The lifetime survival of the patients with cancer (up to 50 years) was 
obtained using linear extrapolation of a logit-transformed curve of the survival 
ratio between the cancer cohort and reference population, under the assumption 
of a constant excess hazard mode (29, 30).  The technical details were summarised 
as follows:
The survival ratio between the survival functions of the patient and the age- 
and sex-matched reference populations is defined by the formula: W (t) = S (t | 
patient population) /S (t | reference population).  Because the patient with MPM 
generally has a worse survival than the reference population, the value of W (t) 
initially equals 1 in the beginning of the follow-up (at the time point of diagnosis), 
and then gradually decrease due to disease-associated excess mortality.  The 
value of W (t) ranges between 0 and 1, so direct linear regression for its temporal 
trend is not applicable.  We therefore  used  the  logit  transformation of W (t), i.e., 
logit W (t) = log[W (t) / (1-W (t) ) ].  A higher logit W (t) value corresponds to a 
higher W (t) value, but the range of  values was transformed from 0 ~ 1 to that of 
-∞ ~+∞ .  Furthermore, if the disease-associated excess hazard remains constant 
over time, the curve of the logit of W (t) will converge to a straight line, as proven 
mathematically by Fang et al (29).
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In practice, the extrapolation process consists of three steps.  First, a plot of 
logit W (t) over time is created.  The time point Ts after which the logit W (t) curve 
becomes a nearly straight line is then identified.  Second, we fit a simple linear 
regression for logit W (t) from Ts to the end of follow-up Tf , that is:
 
where the noise term Nt is independently and normally distributed with 
mean 0 and variance δ2.  Finally, given the least squares estimates of the two 
parameters, α and β , the long-term survival curve of patient population beyond 
the follow-up limits is projected as:
 
The standard error of survival estimates was obtained through a bootstrap 
method by implementing the extrapolation process with data simulated by 
repeatedly sampling with replacement from the real dataset 100 times.
Estimation of the expected years of life lost (EYLL) 
The EYLL for a specific disease was defined as the lifetime survival 
difference between the disease cohort and an age- and gender-matched reference 
population.  EYLL provides us with an estimation of the magnitude to which a 
patient’s life is shortened by the malignancy and therefore it can be regarded as 
an indicator of the total cancer burden as experienced by the society as a whole 
(31).  We estimated the average EYLL by calculating the difference in the areas 
under the long-term survival curves between the cohort of cancer patients and the 
age- and gender-matched reference population.  To facilitate the estimation, we 
used the ISQoL software, which was built in the R statistical package and can be 
freely downloaded from http://www.stat.sinica.edu.tw/jshwang.
Measurement of lifetime direct medical costs
In this study, we aimed to estimate the lifetime direct medical cost from the 
perspective of NHI for a case of MPM.  We used the NHIRD data for the period 
from 1 January 1997 to 31 December 2008 to establish the cohort of MPM 
patients for the estimation of the lifetime healthcare expenditures.  The total 
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lifetime direct medical cost of a patient refers to all the direct healthcare 
expenditures paid by the NHI from the date of cancer diagnosis until the date of 
death.  Patients that were alive at the end of 2008 were censored.  The dates of 
death were retrieved from hospitalisation files and the catastrophic illness 
registration files.  By retrieving the reimbursement data from the NHIRD, we 
were able to calculate the average healthcare expenditures spent by the patients 
at each time period t, which can be summed for the lifetime after adjusting for the 
corresponding survival probability at time t.  The effective sample size in each 
month in the follow-up period was applied for the calculation of the average 
monthly healthcare expenditure using the SAS software.  The lifetime healthcare 
expenditure per case was estimated by total cumulative sum of the product of the 
average monthly healthcare expenditure multiplied by the corresponding monthly 
mean survival probability (32), adjusting for the annual discount rate.  To 
illustrate the temporal relationship of lifetime healthcare expenditures, we 
plotted the dynamic changes of total reimbursed expenditures for clinic services 
or emergency room visits, and hospitalisation care since the diagnosis of MPM.
Validation of the Monte Carlo Extrapolation by Comparison with 
the Kaplan-Meier Method
Empirical data from the NHIRD provided an opportunity to cross-validate 
the estimation of survival functions and the actual performance of the Monte 
Carlo extrapolation.  We first included a sub-cohort of patients diagnosed with 
MPM between 1 January 1997 and 31 December 2001.  The sub-cohort was 
initially followed until the end of 2001, or for a period of 5 years.  Then, we 
extrapolated the data through the end of 2008 or for an additional period of 7 
years, using the Monte Carlo method to estimate the mean survival in month. 
For the cohort that was completely followed to the end of 2008, the non-
parametric Kaplan-Meier estimator was applied to calculate the mean survival 
month based on a follow-up of 12 years as the “gold standard” for comparison.  We 
presented the relative bias to show the differences between the Kaplan-Meier 
estimates and those of the Monte Carlo extrapolation method for the NHIRD.  We 
carefully performed validation for MPM patients registered in the NHIRD by 
plotting the survival curves of the Monte Carlo simulation in comparison with the 
Kaplan-Meier method.  Such a validation was not performed on the TCR data 
because of the relatively small sample size (71 cases of MPM during 1997-2001).
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Statistical analysis
The statistical analyses and Kaplan-Meier survival analysis were performed 
using the SAS software, version 9.2 (SAS Institute Inc., Cary, NC, USA).  To apply 
Monte Carlo simulation, we used the ISQoL software (available from http://www.
stat.sinica.edu.tw/jshwang) for the estimation of lifetime survival functions and 
the calculation of EYLL and lifetime healthcare expenditures.  We also performed 
sensitivity analyses considering an annual discount rate of 3% and 5% and with a 
disease duration that included the three months before the date of cancer 
diagnosis.
RESULTS
The descriptive characteristics of the MPM patients are summarised in Table 
1.  The MPM cohort was composed of 144 histopatholigcally verified patients in 
the TCR during 1997 ~ 2005, while the number recorded in the NHIRD during 
1997 ~ 2008 was 503.  It was likely due to the difficulty in diagnosing this cancer 
solely based on pathology, as well as under-reporting and/or misdiagnosis of MPM 
in the cancer registry.  All the estimates were slightly different, although they 
showed a similar trend of substantial burden of disease. For example, the 
successful prevention for MPM would save 15.1 life-years per case, as shown in 
Figure 1, plus the estimated lifetime healthcare expenditures, $19,615 US dollars, 
at an annual discount rate of 3%, while those based on the TCR were 19.1 life-
years and $15,966 US dollars.  The sensitivity analyses with different discount 
rates and disease costs, either after cancer diagnosis or with a disease duration 
that included three months prior to diagnosis, did not have a large effect.
The survivals based on the sub-cohorts of cancer patients established in the 
5-year period were extrapolated to an additional 7 years using the Monte Carlo 
method and then compared with the actual survival months calculated by the 
Kaplan-Meier method that used the complete 12-year follow-up from 1997 to 
2008, as shown in Figure 2.  The relative bias for the two methods based on the 
NHIRD was less than 2%, which indicated a high agreement, as summarised in 
Table 2.
Figure 3 illustrates temporal changes of mean monthly direct medical costs 
with time since diagnosis for clinic services or emergency room visits, and for 
hospitalisation due to MPM, based on the analysis of reimbursement data of the 
NHIRD.  Generally, the healthcare expenditures in the initial phase when the 
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cancer was first diagnosed were the highest.  From the cost changes of the clinic 
services or emergency room visits, we observed a period of relative increase in 
healthcare expenditures from 40 to 55 months since diagnosis.  It may suggest 
that direct medical costs would elevate because of the increased need of clinic 
services or more frequent emergency room visits as the patients survived into the 
terminal phase of disease course, which corresponded to the life expectancy of 3.6 
years or 43 months (95% CI: 32 ~ 55 months).
DISCUSSION
Our study illustrated a practical approach to estimate EYLL and lifetime 
healthcare expenditures for MPM using data from administrative databases.  A 
particular strength of this study is the use of two separate national, population-
based databases, the TCR and NHIRD, with all registered cancer patients and a 
long follow-up period (1997 ~ 2005, and 1997 ~ 2008, respectively).  This enabled 
us to cross-validate the estimates.  Life expectancy estimates for MPM from the 
two databases were relatively close, about a one-year difference, implying the 
validity and comparability of both datasets and the consistency of estimation 
methods.  However, there was a difference of EYLL for mesothelioma estimated 
from the TCR and NHIRD (19.1-15.1 = 4 years).  The difference is likely 
attributed mainly to the different mean ages at diagnosis, i.e., 64.4-59.8 = 4.6 
years.  The MPM patients included in the TCR dataset were those with 
histopathological evidence of disease and were approximately 4 years younger 
than those registered in the NHIRD.  We therefore tentatively concluded that the 
estimates of two datasets, NHIRD and TCR, and the extrapolation method used in 
this study seem acceptable.
Based on a more conservative estimate between the two datasets, the 
successful prevention of MPM would produce substantial health benefits, a gain 
of 15.1 life years per case for the society and financial saving of $19615 US dollars 
for the NHI.  With the advanced development of new technologies, medications, 
and therapies in cancer treatment, the survival of cancer patients will be 
improved and healthcare expenditures will increase.  Thus, the current estimates 
would be lower than the true value of the healthcare expenditure paid by the NHI 
in the future.
For comparative risk assessment, we proposed the use of life years or quality-
adjusted life years (33) gained and financial savings of healthcare expenditures as 
the metric of outcome evaluation for comparison with other benefits gained 
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through different policy investments.  As the call for a globally total ban on 
asbestos is growing louder than ever, there is also a voice on economic benefits 
from the asbestos industry.  The above figures could be used as a lower bound for 
investment of implementing comprehensive controls to prevent asbestos exposure, 
such as protection of the front-line workers who may be in contact with asbestos 
in building modifications and demolition projects (34).  In general, if an effective 
prevention program costs more than it were estimated to save, the residual 
money can be divided by the number of life years saved to obtain the estimate of 
cost-effectiveness, or cost per life year gained, which can be directly compared 
with different policy decisions.  Moreover, a total ban or strict enforcement of the 
national occupational standard for asbestos may provide additional benefits of the 
savings of human capital loss (indirect costs) plus the health benefits of 
preventing non-cancer outcomes (e.g., asbestosis, pleural plaque) related to the 
same exposure, as well as the avoidance of human suffering among cancer 
patients and their families (35).
Asbestos accounts for more than half of the work-related cancer deaths in 
industrialised countries, such as United Kingdom (36).  In principle, occupational 
and environmental cancers are potentially preventable (37, 38), and a substantial 
percentage of cancer occurrences could be prevented through appropriate 
regulatory strategies in occupational health (20, 39).  Many countries are now 
experiencing part of a worldwide epidemic of asbestos-related diseases, especially 
MPM.  Moreover, one mesothelioma case has been overlooked for every four to five 
reported cases, and therefore a signification proportion of mesothelioma were 
under-reported globally (40).  The future trend of MPM epidemic has been 
predicted globally (41) and in many industrialized countries, including Western 
European (10) (Britain (7, 42), France (43), Germany, Italy (44), Netherlands (45) 
and Switzerland), Denmark  (46), Norway (47), United States (48), Australia (49), 
Japan (50)  and Hong Kong (51).  For example, Driscoll et al. reported 43,000 
mesothelioma deaths per year worldwide due to exposure to asbestos (41), while 
Park et al. estimated the global burden of mesothelioma to be 213,200 during 
1994 ~ 2008, which is equivalent to an annual average of approximately 14,200 
cases (40).  In Japan, analyses using an age-cohort model showed there would be 
about 100,000 deaths due to MPM in the next 40 years (50).  In Great Britain, 
projection of male mesothelioma using Bayesian methods reported that 91,000 
deaths of male mesothelioma are predicted to occur from 1968 to 2050 with 
around 61,000 of these occurring from 2007 onwards (42).  All forms of asbestos 
are now banned successfully in 55 countries worldwide (52).  Unfortunately, there 
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are still a considerable number of countries, particularly in Asia, where asbestos 
are still imported and used in various industries; for these countries the number 
of exposed workers are unknown and asbestos-related deaths are under-reported 
(16, 40, 53).  Economic theory suggests that, where the costs of a health hazard 
are not fully recognised and where an industry is allowed to externalise these 
costs, it will operate on an inappropriately large scale.  The global historical 
pattern of asbestos use was consistent with the environmental Kuznets curve, in 
which asbestos use peaked when incomes attained 10,000 ~ 15,000 Geary–
Khamis dollars (GKD) and essentially ceased at income levels over 20,000 GKD 
(54).  Therefore, such a huge economic burden of asbestos to the whole society had 
better be expressed in monetary unit and directly compared with the industrial 
benefits of asbestos to facilitate the total ban of asbestos and elimination of future 
burden of asbestos-related diseases.
Limitations
This study has the following limitations that should be addressed.  Firstly, we 
adopted the insurer’s perspective, and only direct medical costs were estimated in 
this study.  Based on the estimates of U.S. National Institutes of Health, the 2010 
overall annual costs of cancer were $263.8 billion; all healthcare expenditures 
were $102.8 billion, and indirect morbidity costs and mortality costs accounted for 
more than 50% of the total costs of cancer (55).  Moreover, direct medical costs, as 
suggested by the U.S. Environmental Protection Agency, often provide a lower-
bound estimate of the costs of illness (56).  Due to the lack of empirical data on 
the costs of lost productivity due to illness or premature death, our results 
underestimate the cost of illness to the whole society.  Because the estimation of 
cost of illness is generally a lower bound of that of applying the willingness-to-pay 
method, it implies that our results leave the true figure to some extent.  However, 
since we have quantified the EYLL, one may also use these estimates for 
calculating the cost-effectiveness ratio for a prevention program that is able to 
provide the expected number of prevented cancer cases.
Secondly, because the data from the NHIRD were collected primarily for 
health insurance administration use, we are concerned that the follow-up of 
patient survival status may not be comprehensive.  As compared with survival 
analysis in the TCR, the estimates based on the NHIRD were more likely to be 
more conservative, or lower values of estimation.  Using the Kaplan-Meier 
method as the gold standard, we have validated that there is relatively little bias 
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in calculating the survival functions using the Monte Carlo method based on the 
NHIRD data (Table 2 and Figure 2).
Thirdly, the data on disease severity, including cancer staging, and a patient’s 
socioeconomic status were not available in both databases; these factors may 
influence the prognosis of cancer and lifetime cost estimation.  Future studies are 
needed to address the potential effects of these factors, including establishment of 
the NHI on survival and life expectancy for communities with different 
socioeconomic statuses.
Fourthly, asbestos-related diseases include MPM, lung cancer, asbestosis, 
pleural effusion, discrete pleural plaques or diffuse benign pleural fibrosis and 
rolled atelectasis (12).  Only MPM was included in this study because its highly-
specific causal relationship with exposure to asbestos (20), which obviously 
represented a limited proportion of the burden of asbestos-related disease.  For 
example, 5 ~ 7% of all lung cancers can be attributable to occupational exposures 
to asbestos, in addition to mesotheliomas (9).  Moreover, there were no available 
data regarding the occupational exposure to carcinogens in the databases that 
were used in this study.  Cancers caused by occupational agents tend to affect 
younger individuals, especially if the initial exposure to the carcinogen occurs 
early in their working life (57).  Therefore, EYLL and the cost in occupational 
cancer will be higher than non-occupationally related cancers.  The estimates, 
based on all cases of cancer, are more likely an underestimation of the prevention 
benefits of occupational cancers.
CONCLUSIONS
In conclusion, we have proposed a practical approach for measuring EYLL 
and the lifetime healthcare expenditures for MPM, based on the analyses of 
population-based, administrative databases.  The same method could be applied 
in other countries where the administrative databases are accessible to 
researchers.  The total ban of asbestos, including import and use of all forms of 
asbestos in our environment can prevent future occurrence of MPM, to save 15.1 
life year, and $19,615 US dollars per case of MPM.  The quantification of the 
financial burden in the perspective of NHI in this study does not include human 
capital cost, and is an obvious underestimation of total costs incurred by the 
society as a whole.  With the empirical evidence of the financial burden from 
MPM and the loss of EYLL to the society, we hope that the global ban of asbestos 
can be implemented soon.
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Table 1. Characteristics of malignant pleural mesothelioma (MPM) cohort and 
estimated lifetime healthcare expenditures based on Taiwan Cancer Registry (TCR) 
and National Health Insurance Research Database (NHIRD) 
Characteristics Malignant Pleural Mesothelioma
NHIRD
1997-2008
TCR
1997-2005
　Number 503 144
　Age, mean m SD (years) 
　　　[range]
64.4± 14.9
[22-97]
59.8± 14.9
[20-97]
　Median survival (month) 8.4 6.1
　Male % 64.8 72.9
　Life expectancy (years) [95% CI] 3.6 [2.6-4.6] 2.4 [1.1-3.7]
　Expected years of life lost [95% CI] 15.1[14.1-16.1] 19.1 [17.7-20.5]
Lifetime healthcare expenditures (USD) 
　　　　　　　Mean± SE
　　Discount 3%
　　　　After cancer diagnosis 19,615± 2,607 15,966± 3,063
Included duration 3 mo before diagnosis 19,941± 2,607 16,227± 3,063
　　Discount 5%
　　　　After cancer diagnosis 19,420± 2,542 15,640± 2,998
Included duration 3 mo before diagnosis 19,746± 2,476 15,966± 2,998
1 US Dollar (USD) =29.322 New Taiwan Dollar (NTD) in 2010
95% Confidence Interval (CI) 
Standard deviation (SD) 
Standard error (SE) 
Table 2. Estimates of mean survival months of malignant pleural mesothelioma 
(MPM) in 12 years of follow-up using the Monte Carlo method based on the first 5 
years of follow-up data for the National Health Insurance Research Database 
(NHIRD) were compared with the Kaplan-Meier estimates based on 12 years of follow-
up (1997 ~ 2008) 
NHIRD
Cancer
site
12-year follow-up Extrapolation based on the first 5-year follow-up
Kaplan–Meier method Monte Carlo method
Mean
 (month) 
Mean
(month)
Standard error
(month)
Relative bias
(%)
MPM 36.1 35.5 5.7 -1.66
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Figure 1. The shaded area shows the expected yeas of life lost, 15.1 (95% confidence 
internal 14.1 ~ 16.1) years, due to malignant pleural mesothelioma compared with the 
gender-, age-matched reference population estimated by the Monte-Carlo simulation.
Figure 2. Plots of survival curves for validation of the Monte Carlo extrapolation from 
the first 5 years to the 12 years of follow-up in comparison with the Kaplan-Meier 
estimates for the National Health Insurance Research Database (NHIRD) 
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    (a) 
    (b) 
Figure 3. Temporal changes of total direct medical costs for (a) clinic services or 
emergency room visits or (b) hospitalisation due to malignant pleural mesothelioma
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Appendix Figure 1. Distribuation of cases of malignant pleural mesothelioma (MPM) 
diagnosed in the calendar years, for the Taiwan Cancer Registry (TCR) during 1997 ~ 
2005, and the National Health Insurance Research Database (NHIRD) during 1997 ~ 
2008
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